返回成功案例
医疗健康

PanTera secures US$104.1 million in oversubscribed Series A round to accelerate global actinium-225 production

PanTera, a Belgian radioisotope producer, has completed a US$104.1 million (€93 million) oversubscribed Series A fundraising round led by EQT Life Sciences. Additional equity and debt funding brings the total amount raised to US$150 million (€134 million). In addition to EQT Life Sciences, the Series A round was also joined by Kurma Partners, Eurazeo, Korys, Paladin and PMV.

PanTera, an IBA and SCK CEN joint venture, aims to secure the large-scale production of actinium-225 (225Ac), which is one of the most promising alpha-emitting radioisotopes to fight cancer. The funds raised will be used primarily toward the construction of a state-of-the-art production facility in Belgium. This facility will not only enable large-scale production, it will also help fulfill PanTera’s ultimate goal to improve the accessibility of future, innovative cancer therapy based on 225Ac and theranostics.

Oaklins’ team in Belgium acted as the sole financial advisor in this transaction.

联系交易团队

Cédric Michils

董事总经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Bart Delusinne

董事总经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Nicolas Lambers

副总监
布鲁塞尔, 比利时
Oaklins KBC Securities

Michaël Rixhon

副总监
布鲁塞尔, 比利时
Oaklins KBC Securities

Nicholas Matthyssens

高级经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Robin Bundervoet

经理
布鲁塞尔, 比利时
Oaklins KBC Securities

Niels Maes

经理
布鲁塞尔, 比利时
Oaklins KBC Securities

相关交易

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
医疗健康

Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.

NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.

更多信息
Creo Medical Group plc has completed a US$15.7 million equity fundraise
医疗健康

Creo Medical Group plc has completed a US$15.7 million equity fundraise

Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.

更多信息
HD Clinical Ltd. has been acquired by NEXUS AG
医疗健康 | 科技、媒体及通讯

HD Clinical Ltd. has been acquired by NEXUS AG

NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.

更多信息